John Shemo, MD
Addiction Psychiatry · Charlottesville, VANPI 1194754739
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $184 of the $283 with a category attached, or 65.0%. 4 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 35.0% of the total.
Across 7 payments — averaging $40.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$99
- AbbVie$91
- Johnson & Johnson$69
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24
Across 15 payments — averaging $2253.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$34K
What the payments were for
- Food & beverage$18465%
- Education$9935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $99 |
| AbbVie | 1 | $91 |
| Johnson & Johnson | 4 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
How this compares
Too few addiction psychiatry providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 43 | $28,752 |
| Aripiprazole | 68 | $6,335 |
| Lamotrigine ErLamotrigine | 23 | $4,881 |
| Lurasidone Hcl | 11 | $3,241 |
| Bupropion XlBupropion Hcl | 59 | $2,223 |
| Duloxetine Hcl | 41 | $1,864 |
| Escitalopram Oxalate | 170 | $1,783 |
| Quetiapine Fumarate | 120 | $1,633 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,488 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,287 |
| Lamotrigine | 67 | $886 |
| Buspirone Hcl | 38 | $590 |
| Olanzapine | 16 | $480 |
| Lithium Carbonate ErLithium Carbonate | 33 | $477 |
| Propranolol Hcl | 14 | $450 |
Paid to pharmacies, not to this prescriber.
Other addiction psychiatry in Charlottesville
- Mario GomezMidlothian$5K
- Nicholas McClean-RiceParksley$513
- Melissa GrossSuffolk$458
- John ColemanNorfolk$380
- Masoud HejaziDanville$283
- Penelope ZieglerWilliamsburg$202
- Jasra Ali BhatFalls Church$113
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.